Morana Vojnic, MD, MBA

🧠 When standard diagnostics fall short, molecular tools can step in. A recurrent #PXA case—12 years post-resection—remained elusive on imaging, biopsy, and CSF studies. NGS of CSF revealed a BRAF V600E mutation, confirming leptomeningeal recurrence and a therapeutic target. 🔬 #CSF molecular testing is proving to be a powerful, minimally invasive tool in complex neuro-oncology cases. #NeuroOncology #PrecisionMedicine #NGS #CancerDiagnostics #MedicalInnovation onlinelibrary.wiley.com/doi/10.1002/cn… @RandyDAmico_MD @RutgersCancer @RWJBarnabas

🧠🔬 New publication alert: CSF liquid biopsy detecting circulating tumor cells shows strong accuracy for diagnosing leptomeningeal disease (LMD). ✔️ Sensitivity: 77.8% ✔️ Specificity: 100% ✔️ Informed real treatment decisions Integrating CTC analysis + NGS may enable earlier detection and more precise care for patients with metastatic cancer. #NeuroOncology #LiquidBiopsy #CancerResearch #Brainmetastases #Leptomeningealdisease #LMD academic.oup.com/noa/article/do… @RutgersCancer @RWJBarnabas @EditorNeuro @NeuroOnc

Save the Date for the 2nd Annual Brain & Spine Tumor Symposium! 🧠 Sept 24th, 8am - 6pm 165 Somerset Street, New Brunswick, NJ Virtual & In-Person Meeting Learn from national and international experts at @RutgersCancer, NJ's only NCI-designated Comprehensive Cancer Center. #BrainTumor #Neuro #NeuroOncology #BrainCancer @RWJBarnabas @WorldSIOP @ASCO @wfns_neurosurg @ISRSy @oncologynursing @COGorg

Morana Vojnic: Insights from #TTLC 2026 on Secondary Resistance to #EGFR Therapy oncodaily.com/voices/morana-… @oncodaily

🌟 Juan Gomez Marti presenting our work at #ttlc26 📊 “Acquired #NRG1 Fusion as a Resistance to #EGFR Therapy in Lung Cancer.” Collaborative effort between institutions. Thank you to all the collaborators @MLadanyi, Tom Zhang, Sabina Hajiyeva, Marissa Mattar,Rachel Lai, Naveen Menon, Maria Poplawska, Stephen Machnicki and Romel Somwar #LungCancer #Research #LCSM @IASLC

🚨 Exciting news from my former lab! 🚨 Kudos to Romel Somwar and @MLadanyi and team for their excellent publication highlighting the significance of RRAS/RRAS2 mutations as oncogenic drivers in #NSCLC . This work showcases the potential of targeting these mutations with RMC-6236 ! #Oncology #Research #CancerResearch #TargetedTherapy #Mutations #NSCLCResearch @AACR @IASLC @LUNGevity @lcrf_org @JTOonline aacrjournals.org/clincancerres/…

🚀 Excited to announce our latest publication exploring the use of tepotinib for treating recurrent glioblastoma (GBM) with MET alterations. This research highlights the critical role of next-generation sequencing and molecular testing in neuro-oncology, allowing us to uncover treatment options that can significantly impact patient care. We must continue to advocate for our patients at every stage of their journey. A heartfelt thank you to all the authors for their incredible work! #NeuroOncology #Glioblastoma #PrecisionMedicine #MolecularTesting #NextGenSequencing #PatientAdvocacy #CancerResearch #MET @NeuroOnc @RutgersCancer @RWJBarnabas @KUHospital @NorthwesternMed academic.oup.com/nop/advance-ar…

I'm truly honored to have been a part of #BridgingTheGaps in Brain Mets @OncLive This disease state is unfortunately underrepresented in clinical trials, despite its significance, with approximately 200,000 cases diagnosed annually in the US, particularly in oncogene-driven cancers. There has been remarkable progress in this field over the past few years, and there’s still more to achieve! A special thank you to @BrainTumorDoc and @PTarantinoMD for the invitation, as well as to all the distinguished participants. It was an excellent discussion with a group of experts from various branches. @ARWTMD @DrAMansouri @JAMouabbi @BRicciutiMb @lungoncdoc and others. #neurooncology #brainmets

📚Check this out! With fellow TECAG members and guidance from KOLs, we put together a list of papers published in 2025 that are most relevant to #fellows w 2–3 picks per subspecialty. 🙏Hope it is helpful. 🎉Happy New Year! 🎊🎈 #MedEd #Trainee #OncMedEdCop @ASCO

Another fantastic interview with @Moranaaa of @RWJBarnabas is in the books! Dr Vojnic discussed how MGMT methylation status can be used to guide decisions around temozolomide re-treatment and its more selective use in this setting. Visit our site to learn more! @NeuronC #SNO2025

Fantastic first day! #CancerNJ2025 #neurooncology

Our Neuro-Oncology session has started with experts Dr. Jonathan Sherman, Dr. Morana Vojnic, Dr. Andrew Brown, and Dr. Nicholas DeNunzio! 🧠 #CancerNJ2025 @RutgersCancer @RWJBarnabas @RWJUH @RWJMS @CBMCNJ @ShermanMDneuro @Moranaaa

🧠 EGFRm NSCLC with CNS Mets? There’s new hope! 🚀 First-ever trial of amivantamab + lazertinib in: 🧩 Brain metastases (BrM) 🧩 Leptomeningeal disease (LMD) 📍 All post-osimertinib ± chemo 👨‍🔬 Results: 🧠 BrM cohort (n=20) ✅ ORR: 50% 🎯 Intracranial ORR: 40% ⏱️ PFS: 5.8 mo ❤️ OS: 17.4 mo 🧬 LMD cohort (n=21) ✅ ORR: 33% 💧 CSF CTC ↓ in 67% ⏱️ PFS: 7.8 mo ❤️ OS: 14.4 mo 🧪 MET+ tumors ➜ ORR 77% vs 26% ⚠️ Toxicities: • Skin rash, edema → 💊 dose interruptions in 50% • VTE risk managed with prophylactic anticoagulation 🩸 🧬 Resistance: MAPK pathway mutations (🧩 KRAS, NRAS, BRAF) in 23% 📢 Takeaway: Feasible + active in BrM/LMD ➜ Include LMD in future trials! 📖 Chen MF et al. J Thorac Oncol. 2025. 🔗 doi.org/10.1016/j.jtho… #OncoTwitter #MedTwitter #EGFR #NSCLC #LungCancer #BrainMets @myesmo @esmo_open @IASLC @JTOonline

Let me introduce you to the typical patient who is able to meet all 40 or so cancer clinical trial eligibility criteria of a usual sponsored trial + allow me to bring to your attention this great paper by @bherzbergmd (open access) highlighting the very restrictive nature of case-in-point K-Ras focused trials with actionable items for improvement so not only Superman/Superwoman could have access to exciting novel drugs! pubmed.ncbi.nlm.nih.gov/40845174/

@ipreeshagul @HyeinJeon_MD @christine_lovly So important to emphasize this! Leads to treatment and sometimes even diagnosis changes when looked at in #neurooncology. Thank you for sharing!

Thank you @christine_lovly for highlighting the challenges of NGS interpretation. We need to streamline and simplify so that we don’t miss targetable alterations that could impact one’s life! Go for 2nd opinion , phone a friend! #DCLung25

Dr. Morana Vojnic @Moranaaa @RWJBarnabas presenting now on all things brain! Amazing summary of key takeaways on CNS penetrating therapies and how to measure it! #lcsm

Congratulations to @RutgersCancer @RWJBarnabas Dr. Morana Vojnic @Moranaaa on receiving the Women Leaders in Oncology @WeAreWLO Woman Oncologist of the Year 2025 Award at the Leadership Empowerment and Development conference! Read more ➡️ cinj.org/rutgers-cancer…

I am truly grateful to the #LEAD2025 organizers for this honor. Humbled and inspired to continue moving the needle and pay it forward. #Womeninmedicine #Leadership #Mentorship @JulieBrahmer @KatieLaiMD_MPH @AnaVManana @rachnatshroff @BioAscend @WeAreWLO

Join us Sept 29 at Westin Times Square to review key updates from World Lung 2025 w/ special guests: @Moranaaa @BHenickMD @NickRohsMD Plus a WCLC potpourri mashup with NYC hem/onc fellows!!

Thank you to all who attended and participated at the Inaugural Brain Tumor Symposium at @RutgersCancer @RWJBarnabas on September 25th, 2025. On behalf of the organizing committee I want to particularly thank our whole team who made this happen. Thank you to our guest speakers: Roger Stupp Rebecca Brown Amber Barbach James Rutka Doug Kondziolka Hugues Duffau Eric Bouffet Arjun Saghal @RandyDAmico_MD Organizing Committee: @Moranaaa @ShermanMDneuro Nicholas DeNunzio Nehal Parikh Anil Nanda @theABTA @NBTStweets @glioblastomaorg @OncLive And a special thank you to all our sponsors! #neurooncology #braintumors #CNSmets #GBM #cancer See you all next year!